Splenic marginal zone lymphomas with peripheral CD5 expression

We report 4 cases of splenic marginal zone lymphoma (SMZL) with peripheral CD5 positive, B-cell lymphocytosis. This unusual immunophenotypic discordance raises dilemmas in the diagnostic approach of these patients. In addition, this association may be related to a more aggressive clinical course, as 3 out of 4 of our patients died from progressive disease.

haematologica 2004; 89:113-114 (http://www.haematologica.org/journal/2004/1/113)

Splenic marginal zone lymphoma (SMZL) is a B-cell neoplasm with an indolent clinical course, characteristic histologic pattern of involvement and a non-specific immunophenotypic profile. The lymphomatous cells express surface immunoglobulin of IgM and IgD class, are CD19, CD22, CD20, CD79a positive and CD5, CD10, CD23, CD43, cyclin D1 negative.^{1,2} This immunophenotype differentiates SMZL from follicular and mantle cell lymphomas (MCL), as well as from B-chronic lymphocytic leukemia (B-CLL). However, the lack of specific immunophenotypic markers for SMZL creates problems for the differential diagnosis of SMZL from immunocytoma/lymphoplasmacytic lymphoma. Moreover, CD5 expression has been reported in histologically typical marginal zone B-cell lymphomas.^{3,4} This aberrant CD5 expression has been thought to be a marker for early dissemination and aggressive disease in some patients.

We studied four patients with splenomegaly and lymphocytosis. Peripheral blood smears showed monocytoid Bcells, centrocyte-like cells and varying percentages of villous lymphocytes (Figure 1A). Flow cytometry of the peripheral blood revealed an IgMDĸ, CD19⁺, bright CD20⁺, CD79b⁺, CD79a⁺ and FMC7⁺ B-cell population, co-expressing the CD5 molecule in all 4 cases. None of the cases expressed CD23, CD43, CD10, CD103 or cyclin D1. Bone marrow biopsies revealed a lymphomatous infiltration by small lymphocytes, which ranged from 40-70%. In all cases the pattern of distribution was mainly intrasinusoidal combined, to a lesser extent, with interstitial infiltration, a pattern which has been considered suggestive of possible SMZL.¹

Immunohistochemically the cells were identified as CD20⁺, CD5⁺, CD10⁻, cyclin D1-, and CD23⁻. Subsequently, all patients underwent diagnostic and therapeutic splenectomy which established the diagnosis of SMZL according to the criteria of the WHO classification.⁵ The reactive germinal centers were replaced by small round lymphocytes with effacement of the normal follicle mantle. This zone was fused with small to medium size lymphocytes, resembling marginal zone cells (Figures 1B, C). The immunophenotype on frozen and paraffin-embedded sections was CD5 negative using BL1a (Immunotech) and 4C7 (Ventana) monoclonal antibodies, respectively. In each case, small reactive T lymphocytes were strongly positive for CD5, CD43 and CD45RO and served as an internal positive control. No cyclin D1 expression was detected. One year later, three patients (cases #1, 3 and 4) developed, massive lymphadenopathy. Lymph node and bone marrow biopsies from these patients were characterized by clusters of CD20+, CD5+ large lymphocytes. The patients had no clinical remission following treatment with CHOP and died from infection. The demographic, clinical, and serological characteristics as well as the outcome of the patients are illustrated in Table 1. We describe 4 cases of histologically




Figure 1A. Lymphocytes with polar villous projections in the peripheral blood of case #4 (May-Grünwald Giemsa stain $\times 100$). B. Splenic biopsy of the same patient: splenic marginal zone lymphoma showing infiltration of white and red pulp. (Hematoxylin-eosin stain $\times 400$). C. Lymphomatous cells surrounding residual germinal centers (anti-CD21 staining $\times 630$).

typical SMZL with aberrant CD5 positive expression on peripheral and bone marrow B-lymphocytes but CD5 negativity on splenic specimens. The lack of cyclin D1 expression in all cases was strong evidence against a diagnosis of MCL. Moreover the absence of CD23 and the strong expression of CD22, FMC7, CD79b and CD79a (ZL 7.4) excluded B-CLL. In none of these cases was an intravascular pattern of infiltration observed.⁶ The discordance between CD5 negative splenic and CD5 positive peripheral as well as bone marrow lymphomatous cells has already been reported in isolated

	Patient #1	Patient #2	Patient #3	Patient #4
	π1	π ∠	# J	<i>n-</i> r
Age (years)	72	44	68	75
Sex	Male	Female	Female	Female
Hb (g/dL)	14.4	13.7	12.1	10,9
B lymphocytes/(×10 ⁹)L	. 16.6	13.5	40.5	20.1
Platelets ($\times 10^{9}$)	143.000	114.000	95.000	110.000
Monoclonal band	-	-	lgMκ	-
Hepatomegaly (cm)	4	-	4	5
Splenomegaly (cm)	17	12	20	22
Spleen weight (g)	2.250	1.770	2.725	2.900
Splenic hilum	+	-	+	+
lymphadenopathy				
Peripheral	-	-	-	-
lymphadenopathy				
Bone marrow	+	+	+	+
infiltration				
Therapy	CHOP	CHOP	None	CHOP
Autoimmune	-	-	- F	lashimoto's
manifestations				thyroiditis
			AHA	,
Outcome	PG-death	SD	PG-death PG-death	
Follow-up (years)	1	5	1	2

Table 1. The demographic, clinical, and serological char-
acteristics and outcome of the patients.

AHA: autoimmune hemolytic anemia; SD: stable disease; PG: progressive disease; CHOP: cyclophosphamide, vincristine, doxorubicin, prednisolone.

cases of SMZL.⁷⁸ Differences in the sensitivity of CD5 detection the techniques used (flow cytometry versus immunohistochemistry) or the intensity of the CD5 expression in different tissues have been implicated. However this phenomenon could also be attributed to microenvironmental homing factors on circulating B cells, according to the differentiation hypothesis of CD5⁺ B-cell ontogeny.⁹ In our patients the CD5⁺ tumor cells could perhaps have corresponded to CD5 negative tumor cells that began to express CD5 after migrating from the spleen to the bone marrow microenvironment, either through antigen-driven processes or as a result of inappropriate B-cell responses to the local cytokine network.

Three out of our four CD5⁺ SMZL patients died from progressive disease, while 17 other patients with classic CD5 negative SMZL followed up in our department had an indolent disease. This suggests that neoplastic cells become capable of tumor progression after acquisition of the CD5 marker.¹⁰ However, the co-existence of more than one different B-cell clone could not be excluded since molecular studies of the involved tissues were not performed.

In summary, SMZL may be associated with CD5-positive peripheral blood lymphocytosis. Clinicians and pathologists must be aware of this unusual association in order to reach a correct diagnosis. Furthermore, this disease, unlike CD5negative SMZL, seems to have an aggressive clinical course. On the other hand, the heterogeneity of SMZL has been clearly illustrated by several reports in this journal.¹¹⁻¹⁴

,* Stavroula Giannouli,* George Paterakis, ° Panayiotis D Ziakas,* Dimitra Anagnostou,* Michalis Voulgarelis*

*Department of Pathophysiology, School of Medicine, National University of Athens, 75 Mikras Asias St, 115 27, Athens, Greece; °Immunology Department and National Histocompatibility Center General District Hospital of Athens G. Gennimatas, Athens, Greece; *Department of Haemopathology, Evangelismos Hospital, Athens, Greece

Key words: splenic marginal zone lymphoma, CD5.

Correspondence: Dr. Michalis Voulgarelis, Department of Pathophysiology, School of Medicine, National University of Athens, 75 Mikras Asias St, 115 27, Athens, Greece. Phone: international +302.10.7462648. Fax: international +302.10.7462664. E-mail: mvoulgar@med.uoa.gr

References

- Franko V, Florena AM, Iannito E. Splenic marginal zone lymphoma. Blood 2003;101:2464-72.
 Chacon JI, Mollejo M, Munoz E, Algara P, Mateo M, Lopez L, et
- Chacon JI, Mollejo M, Munoz E, Algara P, Mateo M, Lopez L, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002;100: 1648-54.
- Ferry JA, Yang WI, Zukerberg LR, Wotherspoon AC, Arnold A, Harris NL. CD5⁺ extranodal marginal zone B-cell (MALT) lymphoma. A low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol 1996;105:31-7.
- Ballesteros E, Osborne BM, Matsushima AY. CD5⁺ low-grade marginal zone B-cell lymphomas with localized presentation. Am J Surg Pathol 1998; 22: 201-7.
- 5. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol 1999;111 Suppl 1:S8-12.
- 6 Khalidi HS, Brines RK, Browne P, Koo CH, Battifora H, Medeiros ⊥. Intravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases. Mod Pathol 1998;11:983-8.
- Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Catovsky D. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood 1994;83:1558-62.
- Isaacson PG, Matutes E, Burke M, Catovsky D. The histopathology of splenic lymphoma with villous lymphocytes. Blood 1994;84:3828-34.
- Wortis HH, Teutsch M, Higer M, Zheng J, Parker DC. B-cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes. Proc Natl Acad Sci USA 1995;92:3348-52.
- Hippen KL, Tze LE, Behrens TW.CD5 maintains tolerance in anergic B cells. J Exp Med 2000;191:883-90.
 Sole F, Salido M, Espinet B, Garcia JL, Martinez Climent JA, Grana-
- Šole F, Salido M, Espinet B, Garcia JL, Martinez Climent JA, Granada I, et al. Splenic marginal zone B-cell lymphomas: two cytogenetic subtypes, one with gain of 3q and the other with loss of 7q. Haematologica 2001;86:71-7.
- 12. Dierlamm J. Genetic abnormalities in marginal zone B-cell lymphoma. Haematologica 2003;88:8-12.
- Gazzo S, Baseggio L, Coignet L, Poncet C, Morel D, Coiffier B, et al. Cytogenetic and molecular delineation of a region of chromosome 3q commonly gained in marginal zone B-cell lymphoma. Haematologica 2003;88:31-8.
- Arcaini L, Paulli M, Boveri E, Magrini U, Lazzarino M. Marginal zone-related neoplasms of splenic and nodal origin. Haematologica 2003;88:80-93.

Visit our website at www.haematologica.org to find our full-text articles